Straight to the Point in Triple Negative Breast Cancer
Leronlimab (PRO 140) has demonstrated promising preliminary results in a phase 1b/2 clinical trial (NCT03838367) for patients with metastatic triple negative breast cancer (mTNBC), according to a press release from drug company CytoDyn.
Patients who were given Leronlimab — an antibody blocking CCR5 receptor which is expressed on tumor cells – with Carboplatin experienced a 300% increase in mean time to disease progression, as well as a 450% increase in 1-year survival.
Leronlimab (PRO 140) is administered via injection.
About the Trial
This phase 1b-2 study included 30 patients with mTNBC. In the first stage, patients were divided into 3 experimental cohorts:
In cohort A, patients received 350 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort B treated patients with 525 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort C treated patients with 700 mg of Leronlimab weekly and Carboplatin every 3 weeks.
The trial enrolled patients over 18 years of age who had expression of CCR5 on their cancer cells by immunohistochemistry, IHC, test.
“We are very excited about these preliminary results and are eager to discuss the next regulatory steps based on [these] data,” Scott Kelly, MD, chief medical officer of CytoDyns and chairman of the board said in a press release. “Based on Leronlimab’s mechanism of action, we believe these results may provide tangible hope for patients suffering from mTNBC, and potentially other forms of cancer.”
What is the current status of Leronlimab (PRO140) in Triple Negative Breast Cancer?
The FDA has granted a Fast-Track designation to Leronlimab (PRO140) for use in combination with Carboplatin for the treatment of patients with CCR5-positive metastatic Triple Negative Breast Cancer, TNBC.
Take home message
Talk to us so see if we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039